MOVENTIG (naloxegol), peripheral opioid receptor antagonist laxative

No clinical benefit demonstrated in the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives. 

• MOVENTIG has Marketing Authorisation in the treatment of opioid-induced constipation in adults who have had an inadequate response to laxatives.
• After 12 weeks of treatment, the effect size in favour of naloxegol 12.5 mg/day and 25 mg/day was modest versus placebo and the efficacy at the daily dose of 12.5 mg/day was poorly established in patients with non-cancer pain.
• Efficacy and safety have not been assessed in patients with cancer pain.